Shionogi & Co., Ltd. today announced that its group-wide efforts to combat antimicrobial resistance (AMR) have been highly rated in the Antimicrobial Resistance Benchmark 2026 published by the Netherlands-based non-profit organization, Access to Medicine Foundation. Shionogi was ranked second among leading global research-based pharmaceutical companies.
Shionogi Press Release